Low-dose oral naloxone reverses opioid-induced constipation and analgesia

被引:163
作者
Liu, MW
Wittbrodt, E
机构
[1] St Joseph Med Ctr, Dept Anesthesia, Div Chron Pain Management, Baltimore, MD USA
[2] Philadelphia Coll Pharm & Sci, Philadelphia, PA 19104 USA
关键词
oral naloxone; constipation; opioids; cancer pain; nonmalignant pain;
D O I
10.1016/S0885-3924(01)00369-4
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The most common side effect of opioid therapy is constipation. It is often difficult to treat and is believed to be primarily a peripheral effect. Single large doses of oral naloxone have been shown to be efficacious in reversing opioid-induced constipation. However, they often cause the unwanted side effect of analgesia reversal. This study evaluated the effects on constipation and analgesia of low doses of oral naloxone given three times daily. Patients taking stable doses of opioids with complaints of constipation were recruited for this double-blind, randomized, placebo-controlled study. Patients were given 4 mg or 2 mg of oral naloxone, or placebo, three times daily. Stool frequency and symptoms related to constipation were recorded daily. Patients also recorded the daily amount of analgesics required to maintain pain control. Nine patients were recruited for the study. All the patients who received oral naloxone had some improvement in their bowel frequency. Three of the patients also experienced reversal of analgesia, including one who had complete reversal of analgesia. This study demonstrates that reversal of analgesia still occurred despite dividing the oral naloxone into very low doses relative to the total dose of opioid used. Patients using high doses of opioids appear to be the most vulnerable to the antalgesic effect of oral naloxone. J Pain Symptom Manage 2002;23:48-53. (C) U.S. Cancer Pain Relief Committee 2002.
引用
收藏
页码:48 / 53
页数:6
相关论文
共 25 条
[1]   A constipation scoring system to simplify evaluation and management of constipated patients [J].
Agachan, F ;
Chen, T ;
Pfeifer, J ;
Reissman, P ;
Wexner, SD .
DISEASES OF THE COLON & RECTUM, 1996, 39 (06) :681-685
[2]  
*AM PAIN SOC, 1992, PRINC AN US TREATM A, P23
[3]   DEMONSTRATION OF A SPECIFIC DYNORPHIN RECEPTOR IN GUINEA-PIG ILEUM MYENTERIC PLEXUS [J].
CHAVKIN, C ;
GOLDSTEIN, A .
NATURE, 1981, 291 (5816) :591-593
[4]  
Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
[5]   TREATMENT OF OPIOID-INDUCED CONSTIPATION WITH ORAL NALOXONE - A PILOT-STUDY [J].
CULPEPPERMORGAN, JA ;
INTURRISI, CE ;
PORTENOY, RK ;
FOLEY, K ;
HOUDE, RW ;
MARSH, F ;
KREEK, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) :90-95
[6]   Insights into opioid action in the intestinal tract [J].
DeLuca, A ;
Coupar, IM .
PHARMACOLOGY & THERAPEUTICS, 1996, 69 (02) :103-115
[7]   ADVERSE-EFFECTS OF DRUGS USED IN THE MANAGEMENT OF CONSTIPATION AND DIARRHEA [J].
GATTUSO, JM ;
KAMM, MA .
DRUG SAFETY, 1994, 10 (01) :47-65
[8]   NALOXONE [J].
HANDAL, KA ;
SCHAUBEN, JL ;
SALAMONE, FR .
ANNALS OF EMERGENCY MEDICINE, 1983, 12 (07) :438-445
[9]  
KONTUREK SJ, 1980, AM J GASTROENTEROL, V74, P285
[10]  
Latasch L, 1997, ANAESTHESIST, V46, P191, DOI 10.1007/s001010050390